Wang, Jhi-Joung MD, DMS*,; Ho, Shung-Tai MD, MS†,; Uen, Yih-Huei MD‡,; Lin, Mao-Tsun PhD*,; Chen, Kuan-Ting MD*,; Huang, Jeng-Chai PhD*,; Tzeng, Jann-Inn MD*
Postoperative nausea and vomiting (PONV) is an unpleasant, distressing, and exhausting experience for patients (1–3). PONV is common in patients (53%–72%) undergoing laparoscopic cholecystectomy (LC) for cholelithiasis (4–7). Among the antiemetics currently prescribed for PONV, serotonin subtype 3 antagonists (e.g., ondansetron and granisetron) are expensive (1,2,8–10). Other currently used, lower-cost antiemetics (e.g., anticholinergics, antihistamines, and dopamine receptor antagonists) have side effects, such as sedation, dry mouth, restlessness, changes in arterial blood pressure, and extrapyramidal symptoms (1–10).
Dexamethasone, a corticosteroid, is an inexpensive and effective antiemetic drug, with minimal side effects after a single-dose administration (3,6,11–15). It was first reported in 1981 as an effective antiemetic in patients receiving cancer chemotherapy (12). Since then, dexamethasone has been widely applied in the prevention of nausea and vomiting after chemotherapy (13–15). Dexamethasone also reduces the incidence of PONV (3). The commonly used dose is 8 to 10 mg (3,6), but the minimal effective dose is suggested to be 5 mg for PONV in patients undergoing thyroidectomy (11). Dexamethasone 8 mg is also effective for PONV after LC (6). However, a smaller dose has not yet been evaluated. The aim of the study was to evaluate the efficacy of small-dose dexamethasone (5 mg) on the prophylaxis of nausea and vomiting after LC. Tropisetron (2 mg), a currently used antiemetic for PONV (1,2,8–10), and saline were used as controls.
The protocol was approved by the Hospital Committee for Human Investigation, and informed consent was obtained from each patient. One hundred twenty patients, ASA physical status I or II, undergoing general anesthesia for elective LC were enrolled in a randomized, double-blinded, and placebo-controlled study. Patients with a history of PONV, motion sickness, or major systemic diseases (e.g., hypertension, diabetes mellitus, and morbid obesity) or who had received an antiemetic within 48 h before surgery were excluded.
In the preoperative holding area, patients were allocated randomly to one of the three groups (n = 40 each) by use of a computer-generated random number table. Study medications were prepared by a nurse anesthetist in identical 2-mL syringes to ensure blinding of the anesthesiologists. Immediately after the induction of anesthesia, patients in the Dexamethasone group received dexamethasone 5 mg IV, and those in the Tropisetron group received tropisetron 2 mg IV. Patients in the Placebo group received IV saline. Patients and the investigators who collected the postoperative data were blinded to the randomization.
Anesthesia was induced with propofol 2–2.5 mg/kg IV, glycopyrrolate 0.2 mg IV, and fentanyl 2 μg/kg IV. Tracheal intubation was facilitated with vecuronium 0.15 mg/kg IV. Anesthesia was maintained with 1.0%–2.5% (inspired concentration) isoflurane in oxygen. Ventilation was controlled mechanically and adjusted to keep an end-tidal CO2 partial pressure of 30–40 mm Hg, with an anesthetic/respiratory gas analyzer (Capnomac Ultima; Datex, Helsinki, Finland). Neuromuscular block was maintained with vecuronium IV. After tracheal intubation, a nasogastric tube was placed to promote baseline emptying of the stomach of air and gastric contents. During surgery, patients were positioned in the reverse Trendelenburg position, with the right side of the bed elevated. The abdomen was insufflated with CO2, with an intraabdominal pressure of 10–16 mm Hg. LC was performed under video guidance with four punctures of the abdomen. The IV fluid used during surgery was 0.9% saline. At the end of surgery, glycopyrrolate 0.6 mg IV and neostigmine 3 mg IV were administered for reversal of neuromuscular block, and the trachea was extubated.
After surgery, patients were observed for 24 h. Immediately after surgery, patients were transported to the postanesthetic care unit. During their 1-h stay in the postanesthetic care unit, vital signs were monitored every 15 min, and oxygen saturation was monitored continuously by pulse oximetry. IV saline (0.9%) was given as maintenance fluid for each patient. Tenoxicam 20 mg IV was given routinely for the prevention of postoperative pain. During the following observatory period in the ward, arterial blood pressure, heart rate, and respiratory rate were monitored every 4 h (from 8:00 am to 10:00 pm).
Postoperative pain was assessed with a 10-cm visual analog scale (0 = no pain to 10 = most severe pain) score. When patients complained of pain and requested analgesia, 20 mg of tenoxicam (every 12 h IV) was given.
Nausea and vomiting were evaluated by the following variables: the incidence of nausea and vomiting, episodes of vomiting, rescue antiemetics, and complete responses. For the purpose of data collection, retching (same as vomiting but without expulsion of gastric content) was considered vomiting. A vomiting episode was defined as the events of vomiting that occurred in a rapid sequence (<1 min between events). If events of vomiting were separated by >1 min, they were considered separate episodes. Vomiting that occurred more than four times within 24 h was considered severe vomiting. Rescue antiemetics (metoclopramide 10 mg IV) were given if vomiting occurred or at the patient’s request. The treatment was repeated if necessary. The complete response was defined as no nausea, no vomiting, and no antiemetic medication during a 24-h postoperative period, and this was also the primary efficacy end point of the study. The data of PONV were collected every 4 h (from 8:00 am to 10:00 pm) by direct questioning by a team of nurse anesthetists or by spontaneous complaint of the patients. The patients and the investigators who collected the data were blinded to the patient’s group. Side effects (e.g., headache), if present, were recorded.
Sample size was predetermined by using a power analysis based on the following assumptions: 1) the total incidence of nausea and vomiting in the Saline group would be 60%(6), 2) a 30% reduction in the total incidence of nausea and vomiting (from 60% to 42%) in the treatment groups would be of clinical relevance, and 3) α = 0.05 and β = 0.2 (16). The analysis showed that 40 patients per group would be sufficient (16). A series of one-way analyses of variance was conducted to examine differences among the three groups with respect to parametric variables. If a significant difference was found, the Bonferroni Student’s t-test with correction was used to detect the intergroup differences. The Kruskal-Wallis test was used to determine differences among the three groups with respect to nonparametric variables, followed by the Mann-Whitney U-test for intergroup differences. Categorical variables were analyzed by using a series of 3 × 2 χ2 tests to determine differences among the three groups, followed by 2 × 2 χ2 tests or Fisher’s exact tests, as appropriate, for intergroup differences. All follow-up analyses were corrected for the number of simultaneous contrasts by using the Bonferroni adjustments. A P value <0.05 was considered significant.
Of the 120 patients enrolled in this study, 115 completed it. Five patients who required open cholecystectomy were excluded. The data obtained from the remaining 115 patients were analyzed. The patients’ characteristics (e.g., age, weight, and sex) and the duration of anesthesia, surgery, and CO2 insufflation were similar among the groups (Table 1). During the 24-h observation period, arterial blood pressure, heart rate, and respiratory rate were stable and were not significantly different among groups.
Both the Dexamethasone and Tropisetron groups were significantly different from the Saline group in the following variables: the total incidence of nausea and vomiting, more than four vomiting episodes, the proportions of patients requiring rescue antiemetics, and the incidence of complete responses (Table 2). The differences between the Dexamethasone and Tropisetron groups were not significant.
Within the 24-h observation period, there were no significant differences among groups regarding the percentage of patients requiring rescue analgesics: 15 patients in the Dexamethasone group, 24 patients in the Tropisetron group, and 25 patients in the Saline group. Low visual analog scale pain scores were reported in the three groups: 1.7 (median) in the Dexamethasone group, 2.2 in the Tropisetron group, and 2.1 in the Saline group. The difference among groups was not significant. No significant side effects were found after the use of either dexamethasone or tropisetron when compared with the use of saline.
Laparoscopic surgery has decreased the morbidity associated with cholecystectomy and has become a routine procedure for symptomatic cholelithiasis (17,18). However, a frequent incidence of PONV (53%–72%) has been reported (4–7). In our study, we found that the total incidence of PONV was 64% within 24 hours after patients undergoing LC when no antiemetic was given prophylactically. After pretreatment with dexamethasone 5 mg, the incidence of PONV was significantly reduced to 26%. We also found that dexamethasone 5 mg was as effective as tropisetron 2 mg and was more effective than placebo for this purpose.
Several studies have demonstrated dexamethasone’s efficacy in the prevention of nausea and vomiting associated with chemotherapy (12–15). Dexamethasone also prevents PONV in patients undergoing hysterectomy, tonsillectomy, and thyroidectomy (3,6,11). The dose often used is 8 to 10 mg (3), but the minimal effective dose is 5 mg in patients undergoing thyroidectomy (11). Dexamethasone 8 mg is also effective in reducing the incidence of PONV after LC (6). We further found that dexamethasone 5 mg was also effective for this purpose.
The exact mechanism by which dexamethasone, a corticosteroid, exerts an antiemetic action is not fully understood. However, its antiemetic action, at least in part, may be via the blockage of the corticoreceptors in the nucleus tractus solitarius of the central nervous system (19). Dexamethasone may also exert its antiemetic action through some peripheral mechanism (3,6,11). Dexamethasone, a corticosteroid, has strong antiinflammatory actions and may significantly reduce tissue inflammation around the surgical sites and thus reduce the ascending parasympathetic impulses (e.g., vagus) to the vomiting center and reduce PONV.
The etiology of PONV after LC is not fully understood. Risk factors such as a long period of CO2 insufflation; gall bladder surgery; intraoperative use of isoflurane, fentanyl, and glycopyrrolate; female sex; and postoperative pain may contribute to these episodes (1,2). Because these risk factors may interfere with the interpretation of the study data, we controlled these within the study design. All patients were given LC for cholelithiasis by the same team of anesthesiologists and surgeons. The duration of anesthesia, surgery, and CO2 insufflation and the anesthetic drugs were similar among groups. In addition, after random allocation, sex distributions among groups were similar, as were postoperative pain scores. Therefore, the differences in the occurrence of PONV among groups can be attributed to the study drugs.
Tropisetron, a serotonin subtype 3 receptor antagonist, is primarily used in the prevention of chemo-therapy-related nausea and vomiting (20,21). It has also been applied to the prophylaxis of PONV (8–10). Although 2 and 5 mg of tropisetron are frequently used in the prevention of PONV, 2 mg is recommended for this purpose (8–10,22). Our study is in agreement with this finding.
Cost is an ever-increasing concern in today’s health care system. Prophylactic antiemetic with dexamethasone is relatively inexpensive. Dexamethasone at a dosage of 5 mg costs 18 new Taiwan dollars (equal to US $0.50), which is remarkably less expensive than a similar effective dose of tropisetron 2 mg, which costs US $12. Therefore, dexamethasone 5 mg is a more reasonable choice than tropisetron 2 mg for the prevention of PONV.
In conclusion, prophylactic IV dexamethasone 5 mg significantly reduces the incidence of PONV in patients undergoing LC. At this dose, dexamethasone is as effective as tropisetron 2 mg and is more effective than placebo.
1. Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.
2. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000; 59: 213–43.
3. Henzi I, Walder B, Tramér M. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systemic review. Anesth Analg 2000; 90: 186–94.
4. Naguib M, Bakry AKEI, Khoshim MHB, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. Can J Anaesth 1996; 43: 226–31.
5. Jokela R, Koivuranta M. Tropisetron or droperidol in the prevention of postoperative nausea and vomiting. Acta Anaesthesiol Scand 1999; 43: 645–50.
6. Wang JJ, Ho ST, Liu YH, et al. Dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy. Br J Anaesth 1999; 83: 772–5.
7. Fujii Y, Saitoh Y, Tanaka H, et al. Ramosetron vs granisetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Can J Anaesth 1999; 46: 991–3.
8. Alon E, Buchser E, Herrera E, et al. Tropisetron for treating established postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled study. Anesth Analg 1998; 86: 617–23.
9. Cunningham RS. 5-HT3 receptor antagonists: a review of pharmacology and clinical efficacy. Oncol Nurs Forum 1997; 24: 33–40.
10. Purhonen S, Kauko M, Koski E, et al. Comparison of tropisetron, droperidol, and saline in the prevention of postoperative nausea and vomiting after gynecologic surgery. Anesth Analg 1997; 84: 662–7.
11. Wang JJ, Ho ST, Lee SC, et al. The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study. Anesth Analg 2000; 91: 1404–7.
12. Aapro MS, Alberts DS. Dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med 1981; 305: 520.
13. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer: the Italian Group for Antiemetic Research. N Engl J Med 1995; 332: 1–5.
14. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis: the Italian Group for Antiemetic Research. J Clin Oncol 1997; 15: 124–30.
15. Sehine I, Nishiwaki Y, Kakinuma R, et al. Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis: study 9413. Br J Cancer 1997; 76: 90–2.
16. Lerman J. Study design in clinical research: sample size estimation and power analysis. Can J Anaesth 1996; 43: 184–91.
17. Begos DG, Modlin IM. Laparoscopic cholecystectomy: from gimmick to gold standard. J Clin Gastroenterol 1994; 19: 325–30.
18. Sandor J, Sandor A, Zaborszky A, et al. Why laparoscopic cholecystectomy today? Surg Today 1996; 26: 556–60.
19. Ho CM. Dexamethasone prevents emesis [PhD thesis]. Taipei, Taiwan: National Defense Medical Center, 2001.
20. Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000; 59: 1297–315.
21. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs 1998; 55: 173–89.
22. Capouet V, De Pauw C, Vernet B, et al. Single dose i.v. tropisetron in the prevention of postoperative nausea and vomiting after gynaecological surgery. Br J Anaesth 1996; 76: 54–60.